Assembly Biosciences, Inc. (NASDAQ:ASMB) Insider Sells $15,951.05 in Stock

Assembly Biosciences, Inc. (NASDAQ:ASMB) insider Nicole S. White sold 1,255 shares of Assembly Biosciences stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $12.71, for a total transaction of $15,951.05. Following the completion of the transaction, the insider now directly owns 13,025 shares in the company, valued at $165,547.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Assembly Biosciences Price Performance

Shares of NASDAQ:ASMB opened at $13.15 on Friday. Assembly Biosciences, Inc. has a one year low of $7.69 and a one year high of $20.04. The firm has a 50 day simple moving average of $13.23 and a 200 day simple moving average of $11.19.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Assembly Biosciences stock. Acuitas Investments LLC acquired a new position in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 265,585 shares of the biopharmaceutical company’s stock, valued at approximately $218,000. Acuitas Investments LLC owned about 0.40% of Assembly Biosciences as of its most recent SEC filing. Institutional investors and hedge funds own 19.92% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on ASMB shares. StockNews.com raised Assembly Biosciences from a “sell” rating to a “hold” rating in a report on Friday, April 5th. HC Wainwright reissued a “neutral” rating on shares of Assembly Biosciences in a research note on Monday, April 1st.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.